Compare ACIU & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ACIU | JSPR |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.3M | 68.4M |
| IPO Year | 2016 | N/A |
| Metric | ACIU | JSPR |
|---|---|---|
| Price | $3.14 | $1.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 12 |
| Target Price | $10.00 | ★ $25.60 |
| AVG Volume (30 Days) | 1.3M | ★ 3.8M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,482,957.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $738.95 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $1.39 |
| 52 Week High | $4.00 | $23.11 |
| Indicator | ACIU | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 55.61 | 46.29 |
| Support Level | $2.54 | $1.60 |
| Resistance Level | $2.99 | $1.93 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | 0.03 | 0.03 |
| Stochastic Oscillator | 50.40 | 36.90 |
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.